<DOC>
	<DOC>NCT02711813</DOC>
	<brief_summary>The purpose of this study is to assess whether TAB08 may be beneficial compared to placebo in patients with active Systemic Lupus Erythematosus, not adequately controlled with current concomitant treatment. Secondary purpose is to assess efficacy, safety, pharmacokinetic and pharmacodynamic parameters in this study population.</brief_summary>
	<brief_title>TAB08 in Patients With Systemic Lupus Erythematosus (SLE), Not Adequately Controlled With Current Treatment</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<criteria>Confirmed diagnosis of Lupus Erythematosus according to American College of Rheumatology (ACR) criteria (4 of 11) Active SLE (SLE Disease Activity Index â‰¥ 6) Skin or joint SLE manifestations Lupusnephritis and/or central nervous system affection (neurolupus) Prohibited treatment Pregnant or nursing women Concomitant systemic therapy dosage modification (if any) within 4 weeks before randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>